BIOTECHNOLOGY VALUE FUND L P 4

What Happened
BVF Partners L.P. (part of a group of BVF entities that filed jointly and tied to a Kymera director by footnote) disposed of a total of 1,630,658 shares of Kymera Therapeutics (KYMR) in open-market sales on June 26, 2026. The sales occurred in four blocks at $106.50 per share: 837,914 shares ($89,237,841), 627,597 shares ($66,839,081), 113,289 shares ($12,065,279), and 51,858 shares ($5,522,877), for aggregate proceeds of $173,665,078. These transactions are coded as S (sales).

Key Details

• Transaction date and price: 2026-06-26, all sales at $106.50 per share.
• Total shares sold: 1,630,658; total proceeds: $173,665,078 (~$173.7M).
• Shares owned after transaction: Not specified in the excerpt provided.
• Filing date: Form 4 filed 2026-06-26 (appears to be same-day/timely reporting).
• Notable footnotes: joint filing by multiple BVF entities (F1–F5); sellers disclaim direct beneficial ownership except for pecuniary interests; sales are linked to Partners and an agreement with director Gorjan Hrustanovic who may transfer economic benefit to Partners (F7, Remarks).
• Transaction type: Open-market cash sales (S). No option exercises or awards reported in these trades.

Context
These are institutional/investment-fund sales rather than a straightforward executive personal sale — the filing lists multiple BVF-related entities and notes that beneficial ownership is claimed only to the extent of pecuniary interest. Sales by funds or affiliated entities can be for portfolio rebalancing or liquidity and do not necessarily signal management views on company fundamentals. As always, retail investors should combine insider activity with other fundamentals and disclosures before drawing conclusions.